Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inarigivir intra-hepatic effect in virally suppressed chronic hepatitis B
NCT03932513Phase 2Terminated
- Sponsor
- F-star
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inarigivir soproxil in Chronic Hepatitis B (CHB) (2 arms), sponsored by F-star. Primary endpoints: Change in intra-hepatic immune response at 6 weeks and Change in intra-hepatic anti-viral response at 6 weeks. Started Apr 2019; status: terminated.
02
Drugs
inarigivir soproxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03932513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932513.